INT160240

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 2007
Last Reported 2009
Negated 0
Speculated 1
Reported most in Body
Documents 1
Total Number 2
Disease Relevance 1.20
Pain Relevance 0.15

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.


Pain Term Frequency Confidence Heat
palliative 4 94.84 High High
Pain 1 54.32 Quite High
cytokine 1 5.00 Very Low Very Low Very Low
headache 2 5.00 Very Low Very Low Very Low
cva 8 5.00 Very Low Very Low Very Low
Calcium channel 1 5.00 Very Low Very Low Very Low
Disease Term Frequency Confidence Heat
Non-small-cell Lung Cancer 128 98.28 Very High Very High Very High
Skin Cancer 3 97.20 Very High Very High Very High
Apoptosis 1 96.40 Very High Very High Very High
Malignant Neoplastic Disease 2 95.88 Very High Very High Very High
Disease 34 90.24 High High
Cancer 78 88.24 High High
Disease Progression 11 70.36 Quite High
Cough 1 60.56 Quite High
Dyspnea 1 57.68 Quite High
Pain 1 54.32 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The presented preclinical study was done to investigate the influence of a combined treatment of the epidermal growth factor receptor inhibitor erlotinib and the vascular endothelial growth factor monoclonal antibody bevacizumab in melanoma.
Spec (investigate) Regulation (influence) of erlotinib associated with skin cancer
1) Confidence 0.44 Published 2009 Journal Clin. Cancer Res. Section Abstract Doc Link 19447871 Disease Relevance 0.44 Pain Relevance 0.09
Erlotinib is a small molecule HER-1/EGFR inhibitor that blocks dysregulated EGFR-mediated intracellular signalling in NSCLC, inhibiting proliferation and permitting apoptosis of malignant cells.
Regulation (dysregulated) of Erlotinib associated with malignant neoplastic disease, non-small-cell lung cancer and apoptosis
2) Confidence 0.44 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012552 Disease Relevance 0.76 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox